US FDA new drug expedited review strategies and its implications for ChinaYUAN Lin, SHAO Ming-li2401-2404,2409
Thinking and strategy on standard management of traditional Chinese medicine extractsCONG Luo-luo, WU Bin, ZHANG Jian-wu, SHAO Ming-li2405-2409
Suggestions for clinical trial registration and information sharing in ChinaZONG Xin, DONG Jiang-ping, TAO Xiu-mei2410-2413
Impacts of pharmaceutical industry innovation on patent output: an analysis based on data of three five-year plans in East ChinaHUO Yan-fei, YI Ba-xian, WANG Guang-ping, SHI Sheng-yi, CHEN Ying, LI Chi-rong2414-2419,2433
Pharmaceutical procurement mode in Germany: the primary role of community pharmacyDONG Guo-qing, GUAN Hai-jing, LI Qian, LIU Guo-en, SUN Li-hua2420-2424
Status of quality specification of highly toxic medicinal materials and discussion on related issuesZHOU Yue-hua, XU Zeng-lai, LU Jin-cai2425-2433
Comparison of guidelines for new drug safety pharmacology studies between China and European UnionCHEN Yu-cai, ZHANG Hui-fang, FANG Lian-hua, DU Guan-hua2434-2436
Progress in epidemiology and treatment of benign prostatic hyperplasia and erectile dysfunctionZHOU Yan, CHENG Jing, WANG Jin, TIAN Yu-wei, QI Qu, LI Jia-kui, WU Yong-qian2437-2447,2466
Progress in toxicokinetics research of traditional Chinese medicinesGAO Fang-yuan, YUAN Bo-jun, MA Xiu-juan, XIA Zhen-na, LU Guo-cai2448-2452,2458
Research progress in in vitro models for assessing drug transport across blood-brain barrierZHANG Jun-ying, DIAO Jin-fu, L(U) Qing-lin, WU Chun-yong2453-2458